MedTrace Logo

Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00549679 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2017-07-28

No results posted yet for this study

Summary

This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK256066

PDE4 inhibitor

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-04
Primary Completion
2008-12-15
Completion
2008-12-15

Countries

  • Estonia
  • Finland
  • Germany
  • Netherlands
  • Russia
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00549679 on ClinicalTrials.gov